• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HUANG Fei, ZHU Haijing, ZHOU Xiang, LU Tao, JIAO Yu, TANG Weifang. Progress of Bruton′s tyrosine kinase(BTK)and its inhibitors[J]. Journal of China Pharmaceutical University, 2014, 45(6): 617-624. DOI: 10.11665/j.issn.1000-5048.20140602
Citation: HUANG Fei, ZHU Haijing, ZHOU Xiang, LU Tao, JIAO Yu, TANG Weifang. Progress of Bruton′s tyrosine kinase(BTK)and its inhibitors[J]. Journal of China Pharmaceutical University, 2014, 45(6): 617-624. DOI: 10.11665/j.issn.1000-5048.20140602
shu

Progress of Bruton′s tyrosine kinase(BTK)and its inhibitors

More Information
    Graphical Abstract
    • Abstract
  • Bruton′s tyrosine kinase(BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor(BCR)signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders. A number of BTK inhibitors have progressed through advanced preclinical development to clinical trials. Among them, ibrutinib(PCI-32765, brand name: Imbruvica)demonstrated high clinical activity in B-cell malignancies, especially in patients with chronic lymphocytic leukemia(CLL), mantle cell lymphoma(MCL), and was recently approved by the U. S. Food and Drug Administration. In this paper, the structure and function of BTK are reviewed; preclinical and clinical development of ibrutinib and other novel BTK inhibitors are summarized.
    • FullText(HTML)
    • References (63)
  • [1]
    Tsukada S,Saffran DC,Rawlings DJ,et al.Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia[J].Cell,1993,72(2):279-290.
    [2]
    Vetrie D,Vorechovsky I,Sideras P,et al.The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases[J].Nature,1993,361(6 409):226-233.
    [3]
    de Weers M,Verschuren MC,Kraakman ME,et al.The Bruton′s tyrosine kinase geneis expressed throughout B cell differentiation,from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages[J].Eur J Immunol,1993,23(12):3 109-3 114.
    [4]
    Kawakami Y,Kitaura J,Hata D,et al.Functions of Bruton′s tyrosine kinase in mast and B cells[J].J Leukoc Biol,1999,65(3):286-290.
    [5]
    Rajaiya J,Nixon JC,Ayers N,et al.Induction of immunoglobulin heavy-chain transcription through the transcriptionfactor Bright requires TFII-I[J].Mol Cell Biol,2006,26(12):4 758-4 768.
    [6]
    Liu W,Quinto I,Chen X,et al.Direct inhibition of Bruton′s tyrosine kinase by IBtk,a Btk-binding protein[J].Nat Immunol,2001,2(10):939-946.
    [7]
    Varnai P, Rother KI, Balla T. Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton′s tyrosine kinase pleckstrin homology domain visualized in single living cells[J].J Biol Chem,1999,274(16):10 983-10 989.
    [8]
    Vihinen M,Nilsson L,Smith CI.Tec homology(TH)adjacent to the PH domain[J].FEBS Lett,1994,350(2/3):263-265.
    [9]
    Kang SW, Wahl MI, Chu J, et al. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization[J].EMBO J,2001,20(20):5 692-5 702.
    [10]
    Oppermann FS,Gnad F,Olsen JV,et al.Large-scale proteomics analysis of the human kinome[J].Mol Cell Proteomics,2009,8(7):1 751-1 764.
    [11]
    Nore BF,Mattsson PT,Antonsson P,et al.Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases[J].Biochim Biophys Acta,2003,1 645(2):123-132.
    [12]
    Park H,Wahl MI,Afar DE,et al.Regulation of Btk function by a major autophosphorylation site within the SH3 domain[J].Immunity,1996,4(5):515-525.
    [13]
    Mohamed AJ,Vargas L,Nore BF,et al.Nucleocytoplasmic shuttling of Bruton′s tyrosine kinase[J].J Biol Chem,2000,275(51):40 614-40 619.
    [14]
    Mohamed AJ,Yu L,Backesjo CM,et al.Bruton′s tyrosine kinase(Btk):function,regulation,and transformation with special emphasis on the PH domain[J].Immunol Rev,2009,228(1):58-73.
    [15]
    Satterthwaite AB,Li Z,Witte ON.Btk function in B cell development and response[J].Semin Immunol,1998,10(4):309-316.
    [16]
    Horwood NJ,Page TH,McDaid JP,et al.Bruton′s tyrosine kinase is required for TLR2 and TLR4-induced TNF,but not IL-6,production[J].J Immunol,2006,176(6):3 635-3 641.
    [17]
    Sharma S, Orlowski G, Song W. Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells[J].J Immunol,2009,182(1):329-339.
    [18]
    Yang W, Desiderio S. BAP-135, a target for Bruton′s tyrosine kinase in response to B cell receptor engagement[J].Proc Natl Acad Sci U S A,1997,94(2):604-609.
    [19]
    Rodriguez R,Matsuda M,Perisic O,et al.Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme function in B-cell signaling[J].J Biol Chem,2001,276(51):47 982-47 992.
    [20]
    Akinleye A,Furqan M,Mukhi N,et al.MEK and the inhibitors:from bench to bedside[J].J Hematol Oncol,2013,6(1):27-37.
    [21]
    Furqan M,Mukhi N,Lee B,et al.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application[J].Biomarker Research,2013,1(1):5-14.
    [22]
    Huang T,Karsy M,Zhuge J,et al.B-Raf and the inhibitors:from bench to bedside[J].J Hematol Oncol, 2013,6(1):30.
    [23]
    Doyle SL,Jefferies CA,Feighery C,et al.Signaling by Toll-likereceptors 8 and 9 requires Bruton′s tyrosine kinase[J].J Biol Chem, 2007,282(51):36 953-36 960.
    [24]
    Uckun FM.Bruton′s tyrosine kinase(BTK)as a dual-function regulator of apoptosis[J].Biochem Pharmacol,1998,56(6):683-691.
    [25]
    Kersseboom R,Middendorp S,Dingjan GM,et al.Bruton′s tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells[J].J Exp Med, 2003,198(1):91-98.
    [26]
    Vassilev A,Ozer Z,Navara C,et al.Bruton′s tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex[J].J Biol Chem,1999,274(3):1 646-1 656.
    [27]
    Kil LP, de Bruijn MJ, van Hulst JA, et al. Bruton′s tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia[J].Am J Blood Res,2013,3(1):71-83.
    [28]
    Davis RE,Ngo VN,Lenz G,et al.Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma[J].Nature,2010,463(7 277):88-92.
    [29]
    Brosens LA,Tytgat KM,Morsink FH,et al.Multiple colorectal neoplasms in X-linked agammaglobulinemia[J].Clin Gastroenterol Hepatol,2008,6(1):115-119.
    [30]
    Goodman PA,Wood CM,Vassilev AO,et al.Defective expression of Bruton′s tyrosine kinase in acute lymphoblastic leukemia[J].Leuk Lymphoma,2003,44(6):1 011-1 018.
    [31]
    Backesjo CM,Vargas L,Superti-Furga G,et al.Phosphorylation of Bruton′s tyrosine kinase by c-Abl[J].Biochem Biophys Res Commun,2002,299(3):510-515.
    [32]
    Burger JA, Buggy JJ. Emerging drug profiles: Bruton tyrosine kinase(BTK)inhibitor ibrutinib(PCI-32765)[J].Leuk Lymphoma,2013,54(11):2 385-2 391.
    [33]
    Hutcheson J,Vanarsa K,Bashmakov A,et al.Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus[J].Arthritis Res Ther,2012,14(6):R243.
    [34]
    Ruderman EM,Pope RM.More than just B-cell inhibition[J].Arthritis Res Ther,2011,13(4):125.
    [35]
    Honigberg LA,Smith AM,Sirisawad M,et al.The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy[J].Proc Natl Acad Sci U S A,2010,107(29):13 075-13 080.
    [36]
    Pan Z,Scheerens H,Li SJ,et al.Discovery of selective irreversible inhibitors for Bruton′s tyrosine kinase[J].Chem Med Chem,2007,2(1):58-61.
    [37]
    Herman SE,Gordon AL,Hertlein E,et al.Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765[J].Blood,2011,117(23):6 287-6 296.
    [38]
    Ponader S,Chen SS,Buggy JJ,et al.The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo[J].Blood, 2012,119(5):1 182-1 189.
    [39]
    Kim E,Koehrers,Rosin N,et al.Activity of Bruton′s tyrosine kinase(BTK)inhibitor ibrutinib(PCI-32765)in B-cell acute lymphoblastic leukemia(B-ALL)[J].ASH Annu Meet Abstr, 2012,120(21):2 569.
    [40]
    Advani RH,Buggy JJ,Sharman JP,et al.Bruton tyrosine kinase inhibitor ibrutinib(PCI-32765)has significant activity in patients with relapsed/refractory B-cell malignancies[J].J Clin Oncol,2013,31(1):88-94.
    [41]
    Wang ML,Rule S,Martin P,et al.Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma[J].N Engl J Med,2013,369(6):507-516.
    [42]
    Byrd JC,Furman RR,Coutre SE,et al.Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia[J].N Engl J Med,2013,369(1):32-42.
    [43]
    Byrd J,Furman R,Coutre S,et al.The bruton′s tyrosine kKinase(BTK)inhibitor ibrutinib(PCI-32765)promotes high response rate,durable remissions,and is tolerable in treatment naïve(TN)and relapsed or refractory(RR)chronic lymphocytic leukemia(CLL)or small lymphocytic lymphoma(SLL)patients including patients with high-risk(HR)disease:new and updated results of 116 patients in a phase Ib/II study[C].ASH Annu Meet Abstr, 2012,120(21):189.
    [44]
    Lu K,Wang X.Therapeutic advancement of chronic lymphocytic leukemia[J].J Hematol Oncol,2012,5(1):55.
    [45]
    Fowler N, Advani R, Sharman J, et al. The bruton′s tyrosine kinase inhibitor ibrutinib(PCI-32765)is active and tolerated in relapsed follicular lymphoma[C].ASH Annu Meet Abstr, 2012,120(21):156.
    [46]
    Wilson W, Gerecitano J, Goy A, et al. The Bruton′s tyrosine kinase(BTK)inhibitor,ibrutinib(PCI-32765),has preferential activity in the ABC subtype of relapsed/refractory De Novo diffuse large B-cell lymphoma(DLBCL):interim results of a multicenter,open-label,phase 2 study[C].ASH Annu Meet Abstr, 2012,120(21):686.
    [47]
    Vij R,Chang B,Berdeja J,et al.Early changes in cytokines,chemokines and indices of bone metabolism in a phase 2 study of the Bruton tyrosine kinase(Btk)inhibitor,ibrutinib(PCI-32765)in patients with relapsed or relapsed/refractory multiple myeloma(MM)[C].ASH Annu Meet Abstr, 2012,120(21):4 039.
    [48]
    Sahakian E,Rock-Klotz J,Shah BD,et al.Combination of ACY1215,a selective histone deacetylase 6(HDAC6)inhibitor with the bruton tyrosine kinase(BTK)inhibitor,ibrutinib,represents a novel therapeutic strategy in mantle cell lymphoma(MCL)[C].ASH Annu Meet Abstr, 2012,120(21):1 660.
    [49]
    Burger JA,Keating MJ,Wierda WG,et al.The Btk inhibitor ibrutinib(PCI-32765)in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia(CLL)patients[C].ASH Annu Meet Abstr, 2012,120(21):187.
    [50]
    Blum KA,Christian B,Flynn JM,et al.A phase I trial of the bruton′s tyrosine kinase(BTK)inhibitor,ibrutinib(PCI-32765),in combination with rituximab® and bendamustine in patients with relapsed/refractory non-Hodgkin′s lymphoma(NHL)[C].ASH Annu Meet Abstr,2012,120(21):1 643.
    [51]
    Jaglowski SM,Jones JA,Flynn JM,et al.A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL)and related diseases[C].ASCO Annu Meet Abstr,2012,30(15_suppl):6 508.
    [52]
    Liu L,Di Paolo J,Barbosa J,et al.Antiarthritis effect of a novel Bruton′s tyrosine kinase(BTK)inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamics modeling:relationships between inhibition of BTK phosphorylation and efficacy[J].J Pharmacol Exp Ther,2011,338(1):154-163.
    [53]
    Liu L,Halladay JS,Shin Y,et al.Significant species difference in amide hydrolysis of GDC-0834,a novel potent and selective Bruton′s tyrosine kinase inhibitor[J].Drug Metab Dispos,2011,39(10):1 840-1 849.
    [54]
    Xu D,Kim Y,Postelnek J,et al.RN486,a selective Bruton′s tyrosine kinase inhibitor,abrogates immune hypersensitivity responses and arthritis in rodents[J].J Pharmacol Exp Ther,2012,341(1):90-103.
    [55]
    Mina-Osorio P,Lastant J,Keirstead N,et al.Suppression of glomerulonephritis in lupus prone NZB/W mice by RN486,a selective inhibitor of Bruton′s tyrosine kinase[J].Arthritis Rheum, 2013.doi: 10.1002/art.38047.
    [56]
    Yoshizawa,Toshio,Ariza,et al.Development of a Bruton′s tyrosine kinase(Btk)inhibitor,ONO-4059:efficacy in a collagen induced arthritis(CIA)model indicates potential treatment for rheumatoid arthritis(RA)[C].Arthritis Rheum, 2012,64(Suppl 10):1 660.
    [57]
    Di Paolo JA,Huang T,Balazs M,et al.Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis[J].Nat Chem Biol,2011,7(1):41-50.
    [58]
    Evans EK,Tester R,Aslanian S,et al.Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans[J].J Pharmacol Exp Ther,2013,346.doi: 10.1124/jpet.1113.203489.
    [59]
    Homare E.CC-292,a novel bruton′s tyrosine kinase inhibitor alone and in combination with carfilzomib impacts bone resorption in multiple myeloma by blocking osteoclast sealing zone formation[C].EHA 2013 Congress, 2013,abstr.S543.
    [60]
    Brown J.Phase 1 study of single agent CC-292,a highly selective Bruton′s tyrosine kinase(BTK)inhibitor,in relapsed/refractory chronic lymphocytic leukemia(CLL)and B-Cell non-hodgkin lymphoma(B-NHL)[C].EHA 2013 Congress,2013.Abstr.3793.
    [61]
    Uckun FM,Zheng Y,Cetkovic-Cvrlje M,et al.In vivo pharmacokinetic features,toxicity profile,and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide(LFM-A13),a novel antileukemic agent targeting Bruton′s tyrosine kinase[J].Clin Cancer Res,2002,8(5):1 224-1 233.
    [62]
    Mahajan S,Ghosh S,Sudbeck EA,et al.Rational design and synthesis of a novel anti-leukemic agent targeting Bruton′s tyrosine kinase(BTK),LFM-A13[alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)propenamide[J].J Biol Chem,1999,274(14):9 587-9 599.
    [63]
    Bam R,Ling W,Khan S,et al.Role of Bruton′s tyrosine kinase in myeloma cell migration and induction of bone disease[J].Am J Hematol,2013,88(6):463-471.
    • Related Articles

  • Related Articles

    [1]HOU Yurong, FAN Qingfeng, SHI Sunliang, YUAN Yaozuo, ZHANG Mei. Determination of the content of sisomicin sulfate and sodium chloride injection by RP-HPLC[J]. Journal of China Pharmaceutical University, 2018, 49(6): 695-698. DOI: 10.11665/j.issn.1000-5048.20180609
    [2]YAN Zhengyu, SHU Juan, YU Yan, ZHANG Zhengwei, TANG Lu, CHEN Jianqiu. Preparation and application of carbon dots in chloramphenicol determination[J]. Journal of China Pharmaceutical University, 2015, 46(3): 322-327. DOI: 10.11665/j.issn.1000-5048.20150310
    [3]ZHONG Wen-ying, HUANG Bin, CHEN Lin, SHU Chang. Fluorescence resonance energy transfer quenching for determination of vitamin B2[J]. Journal of China Pharmaceutical University, 2011, 42(6): 527-533.
    [4]Determination of Cyclosporin A in Ocular Tissues by HPLC-MS[J]. Journal of China Pharmaceutical University, 2003, (4): 44-47.
    [5]Content Determination and Stability Research on Diclofenac-Zn[J]. Journal of China Pharmaceutical University, 2002, (3): 92-93.
    [6]Determination of Contents of Dextromethorphan Hydrobromide and Guaifenesine in Capsules by HPLC[J]. Journal of China Pharmaceutical University, 1999, (5): 367-369.
    [7]Determination of Norgestrel in Compound Preparation by First Derivative Spectrography[J]. Journal of China Pharmaceutical University, 1995, (4): 246-247.
    [8]HPLC Determination of Diclofenac in Transdermal Receiver Solution[J]. Journal of China Pharmaceutical University, 1994, (6): 342-344.
    [9]A Reversed-Phase HPLC Method for the Determination of Paeoniflorin Content[J]. Journal of China Pharmaceutical University, 1994, (4): 46-48.
    [10]Study on the Content of Tetrahydropalmatine in Corydalis Yanhusuo by SLS-micellar Enhanced Fluorometry[J]. Journal of China Pharmaceutical University, 1993, (6): 345-347.

Catalog

    Get Citation
    PDF
    XML
    Article views (2007) PDF downloads (1832) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：319016

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return